Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Further Demonstrating First-in-Class and Best-in-Disease
March 01, 2026 09:45 ET | Source: Celldex Therapeutics, Inc. - Late…
Fermenta Announces Granting of CEP by EDQM for VITADEE 100 SD, Enabling Accelerated Global Growth
THANE, India, July 30, 2025 /PRNewswire/ -- Fermenta Biotech Limited ("Fermenta"), a pioneer…
